{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:35:20Z","timestamp":1789698920231,"version":"4.0.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HU20C0111"],"award-info":[{"award-number":["HU20C0111"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2019R1A5A2027340"],"award-info":[{"award-number":["NRF-2019R1A5A2027340"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003669","name":"Korea Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["2021-ER1006-00"],"award-info":[{"award-number":["2021-ER1006-00"]}],"id":[{"id":"10.13039\/501100003669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The standard Centiloid (CL) method was proposed to harmonize and quantify global <jats:sup>18<\/jats:sup>F-labeled amyloid beta (A\u03b2) PET ligands using MRI as an anatomical reference. However, there is need for harmonizing and quantifying regional A\u03b2 uptakes between ligands using CT as an anatomical reference. In the present study, we developed and validated a CT-based regional direct comparison of <jats:sup>18<\/jats:sup>F-florbetaben (FBB) and <jats:sup>18<\/jats:sup>F-flutemetamol (FMM) Centiloid (rdcCL).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>For development of MRI-based or CT-based rdcCLs, the cohort consisted of 63 subjects (20 young controls (YC) and 18 old controls (OC), and 25 participants with Alzheimer\u2019s disease dementia (ADD)). We performed a direct comparison of the FMM-FBB rdcCL method using MRI and CT images to define a common target region and the six regional VOIs of frontal, temporal, parietal, posterior cingulate, occipital, and striatal regions. Global and regional rdcCL scales were compared between MRI-based and CT-based methods. For clinical validation, the cohort consisted of 2245 subjects (627 CN, 933 MCI, and 685 ADD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Both MRI-based and CT-based rdcCL scales showed that FMM and FBB were highly correlated with each other, globally and regionally (<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup> = 0.96~0.99). Both FMM and FBB showed that CT-based rdcCL scales were highly correlated with MRI-based rdcCL scales (<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup> = 0.97~0.99). Regarding the absolute difference of rdcCLs between FMM and FBB, the CT-based method was not different from the MRI-based method, globally or regionally (<jats:italic>p<\/jats:italic> value = 0.07~0.95). In our clinical validation study, the global negative group showed that the regional positive subgroup had worse neuropsychological performance than the regional negative subgroup (<jats:italic>p<\/jats:italic> &lt; 0.05). The global positive group also showed that the striatal positive subgroup had worse neuropsychological performance than the striatal negative subgroup (<jats:italic>p<\/jats:italic> &lt; 0.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings suggest that it is feasible to convert regional FMM or FBB rdcSUVR values into rdcCL scales without additional MRI scans. This allows a more easily accessible method for researchers that can be applicable to a variety of different conditions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-022-01099-0","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T12:05:54Z","timestamp":1666267554000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Development and clinical validation of CT-based regional modified Centiloid method for amyloid PET"],"prefix":"10.1186","volume":"14","author":[{"given":"Soo-Jong","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongki","family":"Ham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Hyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeong Sim","family":"Choe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Ju","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyemin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duk L.","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Hwan","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Won","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"issue":"12","key":"1099_CR1","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s00259-017-3749-6","volume":"44","author":"CC Rowe","year":"2017","unstructured":"Rowe CC, Dore V, Jones G, Baxendale D, Mulligan RS, Bullich S, et al. (18)F-Florbetaben PET beta-amyloid binding expressed in Centiloids. Eur J Nucl Med Mol Imaging. 2017;44(12):2053\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1099_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13550-018-0456-7","volume":"8","author":"MR Battle","year":"2018","unstructured":"Battle MR, Pillay LC, Lowe VJ, Knopman D, Kemp B, Rowe CC, et al. Centiloid scaling for quantification of brain amyloid with [(18)F]flutemetamol using multiple processing methods. EJNMMI Res. 2018;8(1):107.","journal-title":"EJNMMI Res"},{"issue":"1","key":"1099_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1):1\u201315 e1-4.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"1099_CR4","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.jalz.2018.06.1353","volume":"14","author":"M Navitsky","year":"2018","unstructured":"Navitsky M, Joshi AD, Kennedy I, Klunk WE, Rowe CC, Wong DF, et al. Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. Alzheimers Dement. 2018;14(12):1565\u201371.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"1099_CR5","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.2967\/jnumed.115.171595","volume":"57","author":"CC Rowe","year":"2016","unstructured":"Rowe CC, Jones G, Dore V, Pejoska S, Margison L, Mulligan RS, et al. Standardized Expression of 18F-NAV4694 and 11C-PiB beta-Amyloid PET Results with the Centiloid Scale. J Nucl Med. 2016;57(8):1233\u20137.","journal-title":"J Nucl Med"},{"issue":"8","key":"1099_CR6","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1007\/s00259-019-04596-x","volume":"47","author":"SH Cho","year":"2020","unstructured":"Cho SH, Choe YS, Kim HJ, Jang H, Kim Y, Kim SE, et al. A new Centiloid method for (18)F-florbetaben and (18)F-flutemetamol PET without conversion to PiB. Eur J Nucl Med Mol Imaging. 2020;47(8):1938\u201348.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"1099_CR7","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1056\/NEJMoa1603265","volume":"376","author":"RJ Russo","year":"2017","unstructured":"Russo RJ, Costa HS, Silva PD, Anderson JL, Arshad A, Biederman RW, et al. Assessing the Risks Associated with MRI in Patients with a Pacemaker or Defibrillator. N Engl J Med. 2017;376(8):755\u201364.","journal-title":"N Engl J Med"},{"issue":"1","key":"1099_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13195-019-0577-x","volume":"12","author":"SE Kim","year":"2020","unstructured":"Kim SE, Lee B, Park S, Cho SH, Kim SJ, Kim Y, et al. Clinical significance of focal ss-amyloid deposition measured by (18)F-flutemetamol PET. Alzheimers Res Ther. 2020;12(1):6.","journal-title":"Alzheimers Res Ther"},{"issue":"13","key":"1099_CR9","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1007\/s00259-018-4081-5","volume":"45","author":"SH Cho","year":"2018","unstructured":"Cho SH, Shin JH, Jang H, Park S, Kim HJ, Kim SE, et al. Amyloid involvement in subcortical regions predicts cognitive decline. Eur J Nucl Med Mol Imaging. 2018;45(13):2368\u201376.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1099_CR10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/archneur.56.3.303","volume":"56","author":"RC Petersen","year":"1999","unstructured":"Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303\u20138.","journal-title":"Arch Neurol"},{"issue":"3","key":"1099_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263\u20139.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"1099_CR12","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00259-019-04314-7","volume":"46","author":"H Jang","year":"2019","unstructured":"Jang H, Jang YK, Kim HJ, Werring DJ, Lee JS, Choe YS, et al. Clinical significance of amyloid beta positivity in patients with probable cerebral amyloid angiopathy markers. Eur J Nucl Med Mol Imaging. 2019;46(6):1287\u201398.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1099_CR13","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3233\/JAD-180048","volume":"66","author":"SE Kim","year":"2018","unstructured":"Kim SE, Woo S, Kim SW, Chin J, Kim HJ, Lee BI, et al. A Nomogram for Predicting Amyloid PET Positivity in Amnestic Mild Cognitive Impairment. J Alzheimers Dis. 2018;66(2):681\u201391.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1099_CR14","doi-asserted-by":"publisher","first-page":"19576","DOI":"10.1038\/s41598-020-76102-5","volume":"10","author":"SH Cho","year":"2020","unstructured":"Cho SH, Choe YS, Kim YJ, Lee B, Kim HJ, Jang H, et al. Concordance in detecting amyloid positivity between (18)F-florbetaben and (18)F-flutemetamol amyloid PET using quantitative and qualitative assessments. Sci Rep. 2020;10(1):19576.","journal-title":"Sci Rep"},{"issue":"1","key":"1099_CR15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1006\/nimg.2001.0978","volume":"15","author":"N Tzourio-Mazoyer","year":"2002","unstructured":"Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15(1):273\u201389.","journal-title":"Neuroimage."},{"issue":"4","key":"1099_CR16","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.neuroimage.2012.03.020","volume":"61","author":"C Rorden","year":"2012","unstructured":"Rorden C, Bonilha L, Fridriksson J, Bender B, Karnath HO. Age-specific CT and MRI templates for spatial normalization. Neuroimage. 2012;61(4):957\u201365.","journal-title":"Neuroimage."},{"key":"1099_CR17","volume-title":"Seoul neuropsychological screening battery","author":"Y Kang","year":"2003","unstructured":"Kang Y, Na DL, Hahn S. Seoul neuropsychological screening battery. Incheon: Human brain research & consulting co.; 2003."},{"issue":"3","key":"1099_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.12779\/dnd.2019.18.3.77","volume":"18","author":"SH Kang","year":"2019","unstructured":"Kang SH, Park YH, Lee D, Kim JP, Chin J, Ahn Y, et al. The Cortical Neuroanatomy Related to Specific Neuropsychological Deficits in Alzheimer's Continuum. Dement Neurocogn Disord. 2019;18(3):77\u201395.","journal-title":"Dement Neurocogn Disord"},{"issue":"8476","key":"1099_CR19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","volume":"1","author":"JM Bland","year":"1986","unstructured":"Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1(8476):307\u201310.","journal-title":"Lancet."},{"issue":"2","key":"1099_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2967\/jnumed.118.207811","volume":"60","author":"J Lilja","year":"2019","unstructured":"Lilja J, Leuzy A, Chiotis K, Savitcheva I, Sorensen J, Nordberg A. Spatial Normalization of (18)F-Flutemetamol PET Images Using an Adaptive Principal-Component Template. J Nucl Med. 2019;60(2):285\u201391.","journal-title":"J Nucl Med"},{"issue":"6","key":"1099_CR21","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jalz.2019.02.005","volume":"15","author":"V Dore","year":"2019","unstructured":"Dore V, Bullich S, Rowe CC, Bourgeat P, Konate S, Sabri O, et al. Comparison of (18)F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL((R)) approaches: Validation against histopathology. Alzheimers Dement. 2019;15(6):807\u201316.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1099_CR22","doi-asserted-by":"publisher","first-page":"16178","DOI":"10.1038\/s41598-018-34032-3","volume":"8","author":"H Jang","year":"2018","unstructured":"Jang H, Park JY, Jang YK, Kim HJ, Lee JS, Na DL, et al. Distinct amyloid distribution patterns in amyloid positive subcortical vascular cognitive impairment. Sci Rep. 2018;8(1):16178.","journal-title":"Sci Rep"},{"issue":"4","key":"1099_CR23","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3233\/JAD-130461","volume":"40","author":"Y Noh","year":"2014","unstructured":"Noh Y, Seo SW, Jeon S, Lee JM, Kim JH, Kim GH, et al. White matter hyperintensities are associated with amyloid burden in APOE4 non-carriers. J Alzheimers Dis. 2014;40(4):877\u201386.","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"1099_CR24","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1474-4422(11)70077-1","volume":"10","author":"H Barthel","year":"2011","unstructured":"Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10(5):424\u201335.","journal-title":"Lancet Neurol"},{"issue":"8","key":"1099_CR25","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.2967\/jnumed.109.063305","volume":"50","author":"N Nelissen","year":"2009","unstructured":"Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med. 2009;50(8):1251\u20139.","journal-title":"J Nucl Med"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01099-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-022-01099-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01099-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T12:13:19Z","timestamp":1666267999000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-022-01099-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1099"],"URL":"https:\/\/doi.org\/10.1186\/s13195-022-01099-0","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]},"assertion":[{"value":"8 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. The Institutional Review Board of Samsung Medical Center approved the study protocol, and all methods were performed according to the approved guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"157"}}